Hepatitis B surface antigen loss (HBsAg) is a primary therapeutic aim in the management of chronic hepatitis B (CHB), HBsAg levels may be a surrogate marker of infected cells in the liver, and is considered as the only possible quantitative assay for intrahepatic viral load in treated patients with undetected viremia. A rapid HBsAg decline during nucleoside/nucleotide (NA) therapy may identify patients who will show clearance of HBsAg. Currently, there is no consensus on the clinical utility of serum HBsAg monitoring for evaluating patient responses to NA therapy. We aimed to evaluate the possible value of HBsAg quantitation for prediction of treatment response to oral antiviral therapy. This prospective study was carried out on 130 CHB patients treated with oral antiviral therapy in outpatient clinic of
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.